No abstract

Background To assess the resolution of clinical symptoms and radiographic changes in root length and apical diameter in immature permanent teeth with irreversible pulpitis or apical periodontitis with vital inflamed pulp therapy (VIPT).Methods The faculty members at the Ninth People’s Hospital pediatric dentistry department were invited to submit consecutive VIPT cases treated by them, irrespective of outcome, between 2014 and 2016. Clinical success rate, radiographic changes in periapical radiolucency, and apical closure were analyzed, and radiographic changes in the apical diameter and root length were quantified.Results Thirteen of 14 submitted cases of irreversible pulpitis in immature teeth met the inclusion criteria. The follow-up period ranged from 17 to 37 (average, 26.5 ± 7) months. All 13 treated teeth (100%) survived and 12 (92.3%) met the clinical criteria for success throughout the follow-up period, with 92.3% of cases (12 of 13) showing a significant periapical radiolucency decrease and 84.6% (11 of 13) showing complete apical closure at the last visit. The change in apical diameter and root length were obvious. Conclusions Vital inflamed pulp therapy approaches might be of particular value in restoring root development and apical closure and can be an option in treating immature teeth with irreversible pulpitis, even apical periodontitis.

Anatomic tunnel formation and remnant preservation are the recent trends in posterior cruciate ligament (PCL) reconstruction. However, it is difficult to observe the anatomical PCL footprint and perform the operation in the process of remnant-preserving PCL reconstruction. This study describes a single-bundle, transtibial PCL reconstruction technique with anatomic graft passage over the remnant PCL fibers. A femoral tunnel of PCL is created at 2 mm medial to the roof of the intercondylar notch and 3 mm proximal to the margin of the articular cartilage. The tibial insertion of PCL is observed using a figure-of-four position through a posterior trans-septal portal. A tibial bone tunnel is made below the distal center portion of the tibial insertion of residual PCL fibers. The graft is passed over the PCL through the tibial bone tunnel, the space between the anterior cruciate ligament (ACL) and the residual PCL fibers, to the femoral socket and is fixed by the EndoButton and screw. This technique is able to ensure a reasonable intra-articular length and optimal isometry. It has been applied in patients with PCL rupture and posterior instability of the knee joint, and no intraoperative or postoperative complications occurred. Our technology provides a valuable new treatment option for PCL rupture. Future comparative studies are needed to further clarify its beneficial effect.

RNA Binding Proteins (RBPs) interact with RNA and ubiquitously regulate RNA transcripts during their life cycle. Previous works showed that RBPs play fundamental roles in the progression of angiogenesis-related diseases. However, the role of RBPs in skeletal endothelium-dependent bone formation and osteogenesis is unclear. Here, we show that RBP-Ybx1 was strongly reduced in bone vasculature of OVX mice. Endothelial cell-specific deletion of Ybx1 impaired CD31hiEMCNhi endothelium morphology and resulted in low bone mass, while its overexpression promoted angiogenesis-dependent osteogenesis and ameliorated bone loss in OVX mice. Mechanistically, Ybx1 deletion disrupted CD31, EMCN and BMP4 stability in an m5C-dependent manner and blocked endothelial-derived BMP4 release, thereby inhibiting osteogenic differentiation of BMSCs. Administration of recombinant BMP4 protein restored impaired bone formation in Ybx1iΔEC mice. Finally, tail vein injection of CD31-modified PEG-PLGA carrying sciadopitysin, a natural Ybx1 agonist, pharmacologically partially reversed CD31hiEMCNhi vessels decline and improved bone mass both in OVX and aging animals. These findings demonstrated the role of RBP-Ybx1 in angiogenesis-dependent bone formation and provided a novel therapeutic approach for ameliorating osteoporosis.